INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
C07D 215/14, 409/14, 405/14, 417/14, A61K 31/47

(11) International Publication Number: WO 98/14429
(43) International Publication Date: 9 April 1998 (09.04.98)

(21) International Application Number: PCT/US97/17265
(22) International Filing Date: 26 September 1997 (26.09.97)
(30) Priority Data:
08/724,200 1 October 1996 (01.10.96) US

(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).

(72) Inventors: KOLASA, Teodozyj; 118 Walden Lane, Lake Villa, IL 60046 (US). BROOKS, C., D., W.; 2041 Tremont Court, Libertyville, IL 60048 (US). GUNN, David, E.; 40 Wood Street, Hamden, CT 06517 (US).


Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: HETEROARYLMETHOXYPHENYLTHIOALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

(57) Abstract

Compounds having formula (I), wherein W1 and W2 are independently selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted naphthyl; R¹ and R² are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R³ is selected from thienyl, furyl, phenyl, naphthyl, benzo[b]thienyl, alkyl, hydroxyl, and hydrogen; Y an alkylene of one to six carbon atoms; and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) –OR¹, (c) –NR²R³, (d) –NR²SO₂R³ (e) –NH–Tetrazolyl, and (f) glycyl; inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>GE</td>
<td>Georgia</td>
</tr>
<tr>
<td>GH</td>
<td>Ghana</td>
</tr>
<tr>
<td>GN</td>
<td>Guinea</td>
</tr>
<tr>
<td>GR</td>
<td>Greece</td>
</tr>
<tr>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>IE</td>
<td>Ireland</td>
</tr>
<tr>
<td>IL</td>
<td>Israel</td>
</tr>
<tr>
<td>IS</td>
<td>Iceland</td>
</tr>
<tr>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>KE</td>
<td>Kenya</td>
</tr>
<tr>
<td>KG</td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
</tr>
<tr>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>KZ</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>LC</td>
<td>Saint Lucia</td>
</tr>
<tr>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>LR</td>
<td>Liberia</td>
</tr>
<tr>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>MK</td>
<td>The former Yugoslav Republic of Macedonia</td>
</tr>
<tr>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>TM</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>TR</td>
<td>Turkey</td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>VN</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>YU</td>
<td>Yugoslavia</td>
</tr>
<tr>
<td>ZW</td>
<td>Zimbabwe</td>
</tr>
</tbody>
</table>
HETEROARYLMETHOXYPHENYLTHIOALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Technical Field
This invention relates to compounds having activity to inhibit leukotriene biosynthesis, to pharmaceutical compositions comprising these compounds, and to a medical method of treatment. More particularly, this invention relates to bis-heteroarylmethoxyphenylalkyl carboxylate compounds which inhibit leukotriene biosynthesis, to pharmaceutical compositions comprising these compounds and to a method of inhibiting leukotriene biosynthesis.

Background Of The Invention
The leukotrienes are extremely potent substances which produce a wide variety of biological effects, often even when present only in nanomolar to picomolar concentrations. Leukotrienes are important pathological mediators in a variety of diseases. Alterations in leukotriene metabolism have been demonstrated in a number of disease states including asthma, allergic rhinitis, rheumatoid arthritis and gout, psoriasis, adult respiratory distress syndrome, inflammatory bowel disease, endotoxin shock syndrome, atherosclerosis, ischemia induced myocardial injury, and central nervous system pathology resulting from the formation of leukotrienes following stroke or subarachnoid hemorrhage.

Compounds which prevent leukotriene biosynthesis are thus useful in the treatment of disease states such as those listed above in which the leukotrienes play an important pathophysiological role.

The enzyme 5-lipoxygenase catalyzes the first step leading to the biosynthesis of all the leukotrienes and therefore inhibition of this enzyme provides an approach to limit the effects of all the products of this pathway. Agents capable of abrogating the effects of these potent mediators of pathophysiological processes represent a promising class of therapeutic agents (Brooks, D. W., Bell, R. L., and Carter, G. W., in Annual Reports in Medicinal Chemistry, Chapter 8. Pulmonary and Antiallergy Agents. Allen, R. C. ed., Academic Press. 1988).

Toward this end, several new agents have been developed which are useful as leukotriene biosynthesis inhibitors. For example, U.S. Patent No. 4,970,215 to Mohrs. et al. discloses and claims certain 4-(quinolin-2-yl-methoxy)phenylcycloalkyl acetic acids for inhibition of leukotriene synthesis. European Patent Application 0 349 062 to Zamboni. et al. discloses and claims certain quinolylmethoxyphenyl...

**Summary Of The Invention**

The present invention relates to bis-heteroarylmethoxyphenylalkyl carboxylate compounds, their derivatives and pharmaceutically acceptable salts. The compounds have the formula:

![Chemical Structure](image)

wherein W1 and W2 are selected independently at each occurrence from the group consisting of (a) quinolyl; (b) quinolyl substituted with a substituent selected from the group consisting of (b-1) halogen, (b-2) alkyl of one to six carbon atoms, (b-3) haloalkyl of one to six carbon atoms, and (b-4) alkoxy of one to six carbon atoms; (c) benzothiazolyl; (d) benzothiazolyl substituted with a substituent selected from the group consisting of (d-1) halogen, (d-2) alkyl of one to six carbon atoms, (d-3) haloalkyl of one to six carbon atoms, and (d-4) alkoxy of one to six carbon atoms; (e) benzoazolyl; (f) benzoazolyl substituted with a substituent selected from the group consisting of (f-1) halogen, (f-2) alkyl of one to six carbon atoms, (f-3) haloalkyl of one to six carbon atoms, and (f-4) alkoxy of one to six carbon atoms; (g) benzimidazolyl; (h) benzimidazolyl substituted with a substituent selected from the group consisting of (h-1) halogen, (h-2) alkyl of one to six carbon atoms, (h-3) haloalkyl of one to six carbon atoms, and (h-4) alkoxy of one to six carbon atoms; (i) quinoxalyl; (j) quinoxalyl substituted with a substituent selected from the group consisting of (j-1) halogen, (j-2) alkyl of one to six carbon atoms, (j-3) haloalkyl of...
one to six carbon atoms, and (j-4) alkoxy of one to six carbon atoms. (j-5) pyridyl, and (j-6) pyridyl substituted with a substituent selected from the group consisting of (j-6-a) halogen, (j-6-b) alkyl of one to six carbon atoms, and (j-6-c) alkoxy of one to six carbon atoms; (k) naphthyl; (l) naphthyl substituted with a substituent selected from the group consisting of (l-1) halogen, (l-2) alkyl of one to six carbon atoms, (l-3) haloalkyl of one to six carbon atoms, and (l-4) alkoxy of one to six carbon atoms;

R¹ and R² are independently selected from the group consisting of (a) hydrogen, (b) alkyl of one to six carbon atoms, (c) haloalkyl of one to six carbon atoms, (d) alkoxy of one to six carbon atoms, and (e) halogen;

R³ is selected from the group consisting of (a) thienyl, (b) furyl, (c) phenyl, (d) naphthyl, (e) benzo[b]thienyl, (f) alkyl, (g) hydroxy and (h) hydrogen;

Y is an alkenylene of one to six carbon atoms; and

M is selected from the group consisting of (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR⁴ where R⁴ is selected from the group consisting of hydroxyl, hydrogen, alkyl of one to six carbon atoms, (c) -NR⁵R⁶ where R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl of one to six carbon atoms, hydroxy, and alkoxy of one to six carbon atoms, or R⁵ and R⁶ taken together define a five- to eight-membered ring, with the proviso that R⁵ and R⁶ may not simultaneously be hydroxyl, (d) -NR⁴SO₂R⁷ wherein R⁴ is as defined above and R⁷ is alkyl of one to six carbon atoms, (e) -NH-tetrazolyl, and (f) glycinyl.

The present invention also provides pharmaceutical compositions which comprise a therapeutically effective amount of compound as defined above in combination with a pharmaceutically acceptable carrier.

The invention further relates to a method of inhibiting leukotriene biosynthesis in a host mammal in need of such treatment comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound as defined above.

**Detailed Description**

As used throughout this specification and the appended claims, the following terms have the meanings specified.

The term alkyl refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single hydrogen atom. Alkyl groups are exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, and the like.
The terms alkoxy and alkoxyl denote an alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. Representative alkoxy groups include methoxy, ethoxy, propoxy, butoxy, and the like.

The terms alkenyl as used herein refer to monovalent straight or branched chain groups of 2 to 6 carbon atoms containing a carbon-carbon double bond, derived from an alkene by the removal of one hydrogen atom and include, but are not limited to groups such as ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butanyl, 2-butanyl and the like.

The term alkyne denotes a divalent group derived from a straight or branched chain saturated hydrocarbon containing the removal of two hydrogen atoms, for example -CH₂-, -CH₂CH₂-, -CH(CH₃)CH₂- and the like.

The term alkenylene denotes a divalent group derived from a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. Examples of alkenylene include -CH=CH-, -CH₂CH=CH-, -C(CH₃)=CH-, -CH₂CH=CHCH₂- and the like.

The terms alkynylene refers to a divalent group derived by the removal of two hydrogen atoms from a straight or branched chain acyclic hydrocarbon group containing at least one carbon-carbon triple bond. Examples of alkynylene include -CH≡CH-, -C≡C-CH₂-, -C≡C-CH(CH₃) and the like.

The term aryl as used herein refers to a monovalent carbocyclic group containing one or more fused or non-fused phenyl rings and includes, for example, phenyl, 1- or 2-naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like.

The term cycloalkyl as used herein refer to a monovalent saturated cyclic hydrocarbon group. Representative cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptane and the like.

Cycloalkylene denotes a divalent radical derived from a cycloalkane by the removal of two hydrogen atoms.

The term haloalkyl denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.

As used throughout this specification and the appended claims, the term "metabolically cleavable group" denotes a moiety which is readily cleaved in vivo from the compound bearing it, which compound after cleavage remains or becomes pharmacologically active. Metabolically cleavable groups form a class of groups reactive with the carboxyl group of the compounds of this invention (where M is
-OH) well known to practitioners of the art. They include, but are not limited to such
groups as alkanoyl (such as acetyl, propionyl, butyryl, and the like), unsubstituted
and substituted aroyl (such as benzoyl and substituted benzoyl), alkoxy carbonyl
(such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethyilsilyl),
monoesters formed with dicarboxylic acids (such as succinyl), and the like. Because
of the ease with which the metabolically cleavable groups of the compounds of this
invention are cleaved in vivo, the compounds bearing such groups act as pro-drugs of
other leukotriene biosynthesis inhibitors. The compounds bearing the metabolically
cleavable groups have the advantage that they may exhibit improved bioavailability as
a result of enhanced solubility and/or rate of absorption conferred upon the parent
compound by virtue of the presence of the metabolically cleavable group.

In those instances where M is a hydroxyl, the compounds of the present
invention are capable of forming base addition salts. In such instances, the term
"pharmacologically acceptable salts" refers to the relatively nontoxic inorganic and
organic base addition salts of compounds of the present invention. These salts can be
prepared in situ during the final isolation and purification of the compounds, or by
separately reacting the purified carboxyl compound with a suitable base such as the
hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation or
with ammonia, or an organic primary, secondary, or tertiary amine of sufficient
basicity to form a salt with the carboxyl functional group of the compounds of this
invention.

Representative alkali or alkaline earth metal salts include sodium, lithium,
potassium, calcium, magnesium, and the like. Representative organic amines useful
for the formation of base addition salts include ethylamine, diethylamine,
ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. (See, for
example, S. M. Berge, et al., J. Pharmaceutical Sciences, 1977, 66: 1 - 19, which is
incorporated herein by reference).

Similarly, in those instances where the compounds of the present invention
possess a heterocyclic ring moiety containing a basic nitrogen atom, the compounds
are capable of forming acid addition salts. In such cases, the term "pharmacologically
acceptable salts" also refers to the nontoxic inorganic and organic acid addition salts
of compounds of the present invention. These salts can be prepared in situ during
the final isolation and purification of the compounds, or by separately reacting the
purified compound in its free-base form with a suitable inorganic or organic acid and
isolating the salt thus formed. Representative acid addition salts include acetate,
adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate,
butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate.
digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate.
glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride.
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate.
malate, maleate, malonate, methanesulfonate. 2-naphthalenesulfonate, nicotinate,
nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate.
phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate,
thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. (See, for
incorporated herein by reference). Said pharmaceutically acceptable acid and base
addition salts are also contemplated as falling within the scope of the present
invention.

Asymmetric centers may exist in the compounds of the present invention.
The present invention contemplates the various stereoisomers and mixtures thereof.
Individual stereoisomers of compounds of the present invention are made by
synthesis from starting materials containing the chiral centers or by preparation of
mixtures of enantiomeric products followed by separation as, for example, by
conversion to a mixture of diastereomers followed by separation by recrystallization
or chromatographic techniques, or by direct separation of the optical enantiomers on
chiral chromatographic columns. Starting compounds of particular stereochemistry
are either commercially available or are made by the methods detailed below and
resolved by techniques well known in the organic chemical arts.

The preferred compounds of the present invention are those of the above
formula, wherein W1 and W2, at each occurrence, are independently selected from
the group consisting of optionally substituted quinolyl, benzothiazolyl, naphthyl, and
benzimidazolyl. The most preferred compounds of the present invention are those
wherein W1 and W2 are the same at each occurrence and are selected from the group
consisting of (a) quinolyl: and (b) quinolyl substituted with a substituent selected
from the group consisting of (b-1) halogen, (b-2) alkyl of one to six carbon atoms,
(b-3) haloalkyl of one to six carbon atoms, and (b-4) alkoxy of one to six carbon
atoms.

Representative compounds of the invention include, but are not limited to:
1,1-bis(4-(2-quinolylmethoxy)phenyl)eth-1-ylthioacetic acid.
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthioacetic acid.
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthioacetic acid sodium salt.
bis(4-(2-quinolylmethoxy)phenyl)methylthioacetic acid.
(bis(4-(2-quinolylmethoxy)phenyl)-phenyl)methylthioacetic acid,
1,1'-bis(4-(2-quinolylmethoxy)phenyl)-1-pentylthioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-furyl)methylthioacetic acid;
(1-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-thienyl)methylthioacetic acid,
(1-(6-fluoro-2-quinolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-
phenyl)methylthioacetic acid,
(4-(1-methyl-2-benzimidazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-thienyl)methylthioacetic acid,
(4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-furyl)methylthioacetic acid,
1-(4-(2-naphthylmethoxy)phenyl)-1-(4-(2-quinolylmethoxy)phenyl)-1-ethylthioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-2-naphthyl)methylthioacetic acid,
(4-(2-naphthylmethoxy)phenyl)-(4-(2-quinolylmethoxy)phenyl)-2-
naphthyl)methylthioacetic acid.
(2-benzo[b]thiienyl-bis(4-(2-quinolylmethoxy)phenyl))methylthioacetic acid,
(2-benzo[b]thiienyl-4-(1-methyl-2-benzimidazolylmethoxy)phenyl-4-(2-
quinolylmethoxy)phenyl)methylthioacetic acid
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthio-3-propionic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthio-2-propionic acid;
4-(2-benzo[b]thiienylmethoxy)phenyl-bis(4-(2-quinolylmethoxy)phenyl)-methylthio-
3-propionic acid,
(1-(2-benzo[b]thiienyl-4-(2-naphthylmethoxy)phenyl-4-(2-quinolylmethoxy)-
phenyl)methylthio-3-propionic acid.
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthio-2-benzoic acid,
(4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)-methylthio-2-
benzoic acid.
1-(bis(4-(2-quinolylmethoxy)phenyl)-1-ethylthio-2-benzoic acid; and
1-(4-(2-naphthylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)-1-ethylthio-2-
benzoic acid.

**Pharmaceutical Compositions**

The present invention also provides pharmaceutical compositions which
comprise compounds of the present invention formulated together with one or more
non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions
may be specially formulated for oral administration in solid or liquid form, for
parenteral injection, or for rectal administration.

The pharmaceutical compositions of this invention can be administered to
humans and other animals orally, rectally, parenterally, intracisternally,
intravaginally, intraperitoneally, topically (as by powders, ointments, or drops),
buccally, or as an oral or nasal spray. The term "parenteral" administration as used
herein refers to modes of administration which include intravenous, intramuscular,
intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection
comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions,
dispersions, suspensions or emulsions as well as sterile powders for reconstitution
into sterile injectable solutions or dispersions just prior to use. Examples of suitable
aqueous and nonaqueous carriers, diluents, solvents or vehicles include water,
ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the
like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable
organic esters such as ethyl oleate. Proper fluidity can be maintained, for example,
by the use of coating materials such as lecithin, by the maintenance of the required
particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative, wetting
agents, emulsifying agents, and dispersing agents. Prevention of the action of
microorganisms may be ensured by the inclusion of various antibacterial and
antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the
like. It may also be desirable to include isotonic agents such as sugars, sodium
chloride, and the like. Prolonged absorption of the injectable pharmaceutical form
may be brought about by the inclusion of agents which delay absorption such as
aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to
slow the absorption of the drug from subcutaneous or intramuscular injection. This
may be accomplished by the use of a liquid suspension of crystalline or amorphous
material with poor water solubility. The rate of absorption of the drug then depends
upon its rate of dissolution which, in turn, may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a parenterally administered
drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microcapsule matrices of the
drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon
the ratio of drug to polymer and the nature of the particular polymer employed, the
rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the
active compounds. The liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, agar, and tragacanth, and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any nontoxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.


Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Ophthalmic
formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Generally dosage levels of about 1 to about 50, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g., two to four separate doses per day.

**Preparation Of Compounds Of This Invention**

The preparation of compounds of this invention is outlined in Scheme 1 and described as follows. Reaction of a 4,4′-dihydroxybenzophenone derivative I with the requisite heteroaryl)methylhalide(s) of formula W-CH₂X, where X is Cl, Br, or I and W is W¹ and/or W², which are as defined above, in the presence of a suitable base such as K₂CO₃ provides the desired intermediate II. Treatment of compound II with metallo-organic derivatives R³M, preferably organolithium compounds, gives adducts of formula III. Intermediates of formula III are reacted with mercapto-alkylester, HS-Y-COOR⁸ where R⁸ is alkyl and Y is as defined previously, in the presence of a suitable acid, to give the adduct of formula IV. Hydrolysis of the ester, for example using aqueous alkali, provides compounds of formula V wherein R⁸ is H.
Scheme 1

\[
\begin{align*}
\text{I} & \quad \text{W-CH}_2\text{X, DMF, K}_2\text{CO}_3 \\
\text{II} & \\
\text{III} & \quad \text{HS-Y-COOR}^8, \text{acid} \\
\text{IV} & \quad \text{R}^8 = \text{alkyl} \\
\text{V} & \quad \text{R}^8 = \text{H} \\
\text{I} & \quad \text{W-CH}_2\text{X, DMF, K}_2\text{CO}_3 \\
\text{II} & \\
\text{III} & \quad \text{HS-Y-COOR}^8, \text{acid} \\
\text{IV} & \quad \text{R}^8 = \text{alkyl} \\
\text{V} & \quad \text{R}^8 = \text{H}
\end{align*}
\]
The foregoing may be better understood by reference to the following examples which are provided for illustration and are not intended to limit the scope of the invention as it is defined by the appended claims. In the examples below, the starting materials are the intermediates of formula II in Scheme 1 above, prepared from the corresponding 4,4'-dihydroxybenzophenone of formula I and heteroaryl methyl halide(s) of formula W-CH₂X by the methods well known to the persons of ordinary skill in the art.

Example 1

Preparation of 1,1-bis(4-(2-quinolylmethoxy)phenyl)ethyl-1-ylthioacetic acid

\[
\text{\includegraphics[width=0.5\textwidth]{example1.png}}
\]

To a solution of 4,4'-di(2-quinolylmethoxy) benzophenone (992 mg, 2 mmol) in THF (20 mL) at -78°C was added methylmagnesium bromide (3M solution in ethyl ether, 0.8 mL, 2.4 mmol) and the resulting mixture was stirred at room temperature for 12 hours. The mixture was then quenched with saturated aqueous NH₄Cl and extracted with ethyl acetate. The extract was washed with water, brine, dried with anhydrous MgSO₄ and concentrated in vacuo. The residue was chromatographed (silica gel, methylene chloride-ethyl acetate 4:1) to afford 920 mg of 1,1-bis(4-(2-quinolylmethoxy)phenyl)ethanol.

A mixture of 1,1-bis(4-(2-quinolylmethoxy)phenylethanol (300 mg, 0.6 mmol) and ethyl thioglycolate (0.1 mL, 0.7 mmol) in methylene chloride (15 mL) at 0°C was treated with boron trifluoride etherate (0.24 mL, 2 mmol) and the mixture was left at 0°C for additional 1 hour. The mixture was then quenched with saturated solution of NH₄Cl and extracted with methylene chloride. The extract was dried with anhydrous MgSO₄ and concentrated in vacuo. The residue was chromatographed (silica gel, 9:1 methylene chloride-ethyl acetate) to provide 220 mg of ethyl ester of 1,1-bis(4-(2-quinolylmethoxy)phenyl)ethyl-1-ylthioacetic acid.

1 N sodium hydroxide (0.5 mL) was added to a solution of ethyl 1,1-bis(4-(2-quinolylmethoxy)phenyl)eth-1-ylthioacetate from above in dioxane (10 mL) and ethanol (5 mL), and the resulting mixture was stirred at ambient temperature for 3 hours. The organics were removed in vacuo, the residue was diluted with water and acidified to pH 3. The solid was filtered, washed with water, dried under reduced
pressure and recrystallized from methylene chloride-hexane to provide 170 mg of the
title compound: mp 92-94°C; 1H NMR (300 MHz, DMSO-d6) δ 2.00 (s, 3 H), 3.32
(s, 2 H), 5.34 (s, 4 H), 7.02 (d, J = 9 Hz, 4 H), 7.30 (d, J = 9 Hz, 4 H), 7.63 (m, 4
H), 7.78 (m, 2 H), 8.00 (m, 4 H), 8.41 (d, J = 8 Hz, 2 H); MS (DCI-NH3) m/z 587
(M + H)+. Anal. Calc’d. for C36H30N2O4S: C, 73.70; H, 5.15; N, 4.77. Found:
C, 74.24; H, 5.28; N, 4.34.

Example 2
Preparation of (bis(4-(2-quinolylimethoxy)phenyl)-2-thienyl)methylthioacetic acid

To a solution of 4,4'-bis(2-quinolylimethoxy)benzophenone (7.44 g, 15
mmol) in THF (75 mL) was added 2-thienyllithium (16 mL of 1M solution in THF,
16 mmol) and the resulting mixture was allowed to warm to the ambient temperature
(~2 hours). A saturated solution of NH4Cl was added and the mixture was extracted
with ethyl acetate, washed with water, brine, dried (MgSO4) and concentrated in
vacuo. The residue was purified by chromatography (silica gel, 4:1 CH2Cl2/EtOAc)
to provide 5.8 g (65%) of (bis(4-(2-quinolylimethoxy)phenyl)-2-thienyl)methanol.
Recovered was 760 mg (10%) of starting material.

A mixture of alcohol intermediate from above (2.90 g, 5 mmol) and ethyl
mercaptoacetate (0.6 mL, 5.3 mmol) in acetic acid (100 mL) and CHCl3 (20 mL) was
treated with BF3·Et2O (1.75 mL, 15 mmol) and the reaction mixture was stirred at
room temperature for 1 hour. The mixture was poured slowly into saturated aqueous
NaHCO3 and extracted with ethyl acetate, washed with water, 10% NaHCO3, brine,
dried (MgSO4) and concentrated in vacuo. The residue was purified by
chromatography (silica gel, 9:1 CH2Cl2/Et2O) to afford 1.8 g (53%) of ester
intermediate.

To a solution of the ester intermediate from above (2.1 g, 3 mmol) in dioxane
(50 mL) and ethanol (15 mL) was added 1N NaOH (3.5 mL, 3.5 mmol) and the
resulting solution was stirred at room temperature for 3 hours. Water (40 mL) was
added and the organics were removed in vacuo. The water solution was acidified to
pH 3 with 10% citric acid, the solid was filtered and recrystallized from dioxane-
water to provide 1.9 g (97%) of the desired product. mp 99-101°C. $^1$H NMR (300 MHz, DMSO-d$_6$) $\delta$ 3.06 (s, 2 H), 5.35 (s, 4 H), 6.85 (d-d, J = 5 and 2 Hz, 1 H), 6.98 (d-d, J = 5 and 3 Hz, 1 H), 7.06 (d, J = 9 Hz, 4 H), 7.26 (d, J = 9 Hz, 4 H), 7.48 (d-d, J = 5 and 2 Hz, 1 H), 7.62 (m, 2 H), 7.69 (d, J = 8 Hz, 2 H), 7.79 (m, 2 H), 8.01 (m, 4 H), 8.42 (d, J = 8 Hz, 2 H); MS (FAB(+)) m/z 655 (M + H)$^+$; MS (FAB(-)) m/z 653 (M - H)$^-$. Anal. Calc'd. for C$_{39}$H$_{30}$N$_2$O$_4$S$_2$ x 0.75 H$_2$O: C, 70.09; H, 4.68; N, 4.19. Found: C, 70.06; H, 4.73; N, 3.89.

Example 3

Preparation of (bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthioacetic acid sodium salt

![Chemical structure](image)

The desired material was prepared by neutralization of the product of Example 2 according to standard procedures. mp > 80°C (decomp); $^1$H NMR (300 MHz, DMSO-d$_6$) $\delta$ 2.70 (s, 2 H), 5.34 (s, 4 H), 6.88 (d-d, 1 H, J = 1.5 and 4.5 Hz), 6.93 (d-d, 1 H, J = 3 and 4.5 Hz), 7.03 (d, 4 H, J = 9 Hz), 7.26 (d, 4 H, J = 9 Hz), 7.40 (d-d, 1 H, J = 1.5 and 4.5 Hz), 7.62 (m, 2 H), 7.70 (d, 2 H, J = 8 Hz), 7.79 (m, 2 H), 8.01 (m, 4 H), 8.42 (d, 2 H, J = 8 Hz); MS (FAB(+)) m/z 677 (M + H)$^+$, 699 (M + Na)$^+$; FAB(-) m/z 653 (M - Na)$^-$. Anal. Calc'd. for C$_{39}$H$_{29}$N$_2$O$_4$S$_2$Na x 1.5 H$_2$O: C, 66.55; H, 4.58; N, 3.98; Found: C, 66.53; H, 4.33; N, 3.87.

Example 4

Preparation of bis(4-(2-quinolylmethoxy)phenyl)methylthioacetic acid

![Chemical structure](image)

To a bis(4-(2-quinolylmethoxy)phenyl)methanol (0.75 g, 1.51 mmol) in methylene chloride/chloroform (1:1) mixture (8 mL) was added ZnI$_2$ (0.601 g, 1.91
mmol). After 10 minutes ethyl 2-mercaptoacetate (0.239 ml, 2.18 mmol) was added and the mixture was allowed to stir for 14 hours at room temperature. Water was added and the product was extracted with CHCl₃ (2x). The organic layer was washed with water, brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by chromatography (silica gel, 2:1 Hexane/EtOAc) to provide 650 mg of bis(4-(2-quinolylmethoxy)phenyl)methylthioacetic acid ethyl ester.

The ester (0.609 g, 1.01 mmol) was dissolved in a mixture of EtOH:THF (15:5) (20 mL) at room temperature and 1 N NaOH (1.27 mL, 1.27 mmol) was added. The reaction mixture was refluxed for 15 hours and H₂O (50 mL) was added to the mixture. 10% Citric acid was added to pH 3 and the product was extracted with EtOAc (2X). The organic layer was washed with water, brine, dried over MgSO₄ and concentrated in vacuo. The residue was triturated with hexanes and the solid was filtered to give 300 mg of the title compound as a white powder: mp 175-180°C; ¹H NMR (300 MHz, DMSO-d₆) δ 3.02 (s, 2 H), 5.29 (s, 1 H), 5.34 (s, 4 H), 7.03 (d, J = 9 Hz, 4 H), 7.33 (d, J = 9 Hz, 4 H), 7.63 (m, 4 H), 7.79 (m, 2 H), 8.00 (m, 4 H), 8.41 (d, J = 9 Hz, 1 H), 12.51 (br s, 1 H); MS (DCI-NH₃) m/z 573 (M + H)+. Anal. Calc'd. for C₃₅H₂₈N₂O₄S x 1.1 H₂O: C, 70.95; H, 5.14; N, 4.73. Found: C, 71.08; H, 5.11; N, 4.41.

Example 5

Preparation of (bis(4-(2-quinolylmethoxy)phenyl)-phenyl)methylthioacetic acid

![Chemical Structure](image)

To a solution of 4-(2-quinolylmethoxy)phenyl ketone (0.520 g, 1.05 mmol) in anhydrous THF (10 mL) at -78°C phenyl lithium (0.873 mL, 1.57 mmol) was added and the reaction mixture was allowed to warm to room temperature. Water was then added to the reaction mixture and the product was extracted with EtOAc (2X). The organic layer was washed with water, brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was triturated with Et₂O to give 400 mg of (bis(4-(2-quinolylmethoxy)phenyl)-phenyl)methanol as a cream solid.

The title compound was prepared according to the procedure of Example 4, substituting (bis(4-(2-quinolylmethoxy)phenyl)-phenyl)methanol for bis(4-(2-
quinolylmethoxy)phenyl)methanol. mp 89-91°C. 1H NMR (500 MHz, DMSO-d6) δ
2.85 (s, 2 H) 5.34 (s, 4 H), 7.04 (d, J = 10 Hz, 4 H), 7.23 (d, J = 10 Hz, 4 H),
7.25 (m, 1 H), 7.32 (m, 4 H), 7.61 (t, J = 7.50 Hz, 2 H), 7.69 (d, J = 10 Hz, 2 H),
7.78 (t, J = 7.50 Hz, 2 H), 8.01 (dd, J = 11.50, 7.50 Hz, 4 H), 8.42 (d, J = 10 Hz,
2 H); MS (FAB(-)) m/z 647 (M - H)⁻. Anal. Calc'd. for C41H32N2O4S x 0.25 H2O:
C, 75.38; H, 5.01; N, 4.28. Found: C, 75.31; H, 4.97; N, 4.20.

Example 6

Preparation of 1,1-bis(4-(2-quinolylmethoxy)phenyl)-pentylthioacetic acid

![Chemical Structure]

The desired material was prepared according to the method of Example 1, except substituting n-butyllithium for methylmagnesium bromide.

Example 7

Preparation of (bis(4-(2-quinolylmethoxy)phenyl)-furyl)methylthioacetic acid

![Chemical Structure]

The desired material was prepared according to the method of Example 1, except substituting 2-furyllithium for methylmagnesium bromide.

Example 8

Preparation of (4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-thienyl)methylthioacetic acid

![Chemical Structure]
The desired material was prepared according to the procedure of Example 2, except starting with 4-(2-quinolylmethoxyphenyl)-4-(2-benzothienylmethoxyphenyl) ketone.

**Example 9**
Preparation of (4-(6-fluoro-2-quinolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-phenyl)methylthioacetic acid

![Chemical structure of Example 9](image)

The desired material was prepared according to the method of Example 5, except starting with 4-(2-quinolylmethoxyphenyl)-4-(6-fluoro-2-quinolylmethoxyphenyl) ketone.

**Example 10**
Preparation of (4-(1-methyl-2-benzimidazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-thienyl)methylthioacetic acid

![Chemical structure of Example 10](image)

The desired material was prepared according to the method of Example 2 excepting starting with 4-(2-quinolylmethoxyphenyl)-4-(2-benzimidazoyl-methoxyphenyl) ketone.
Example 11
Preparation of (4-(2-benzothiazolymethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-furyl)methylthioacetic acid

The desired material was prepared according to the method of Example 7, except starting with 4-(2-quinolylmethoxyphenyl)-4-(2-benzothiazolymethoxyphenyl) ketone.

Example 12
Preparation of 1-(4-(2-naphthylmethoxy)phenyl)-1-(4-(2-quinolylmethoxy)phenyl)-1-ethylthioacetic acid

The desired material was prepared according to the method of Example 1, except starting with 4-(2-quinolylmethoxyphenyl)-4-(2-naphthylmethoxyphenyl) ketone.

Example 13
Preparation of (bis(4-(2-quinolylmethoxy)phenyl)-2-naphthyl)methylthioacetic acid

The desired material was prepared according to the procedure of Example 1, except substituting 2-naphthyllithium for methylmagnesium bromide.
Example 14
Preparation of (4-(2-naphthylmethoxy)phenyl)-(4-(2-quinolylmethoxy)phenyl)-2-naphthyl)methylthioacetic acid

The desired material was prepared according to the procedure of Example 1, except starting with 4-(2-naphthylmethoxy)phenyl 4-(2-quinolylmethoxy)phenyl ketone and substituting 2-naphthyllithium for methylmagnesium bromide.

Example 15
Preparation of (2-benzo[b]thienyl-bis(4-(2-quinolylmethoxy)phenyl)methylthioacetic acid

The desired material was prepared according to the procedure of Example 2, except substituting 2-benzo[b]thienyllithium for 2-thienyllithium.

Example 16
Preparation of (2-benzo[b]thienyl)-4-(1-methyl-2-benzimidazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)methylthioacetic acid

SUBSTITUTE SHEET (RULE 26)
The desired material was prepared according to the procedure of Example 2, except starting with 4-(2-benzimidazolylmethoxy-1-methyl)phenyl 4-(2-quinolylmethoxy)phenyl ketone and substituting 2-benzo[b]thienyllithium for 2-thienyllithium.

**Example 17**
Preparation of (bis(4-(2-quinolylmethoxy)phenyl)-2-thiencyl)methylthio-3-propionic acid

![Chemical structure diagram]

The desired material was prepared according to the procedure of Example 2, except substituting 3-mercaptopropionic acid for mercaptoacetic acid.

**Example 18**
Preparation of (bis(4-(2-quinolylmethoxy)phenyl)-2-thiencyl)methylthio-2-propionic acid

![Chemical structure diagram]

The desired material was prepared according to the procedure of Example 2, except substituting 2-mercaptopropionic acid for mercaptoacetic acid.
Example 19

Preparation of \((4\text{-}(2\text{-benzo}[b]\text{thienyl} methoxy) phenyl)\text{-}bis(4\text{-}(2\text{-quinoly} methoxy) phenyl) methythio-3\text{-}propionic acid\)

\[
\begin{array}{c}
\text{CH} - \text{O} - \text{C} - \text{S} - \text{S} - \text{COOH}
\end{array}
\]

The desired material was prepared according to the procedure of Example 2, except substituting 2-benzo[b]thienyllithium for 2-thienyllithium and 3-mercapto-propionic acid for mercaptoacetic acid.

Example 20

Preparation of \((4\text{-}(2\text{-benzo}[b]\text{thienyl})4\text{-}(2\text{-naphthyl} methoxy) phenyl)\text{-}4\text{-}(2\text{-quinoly} methoxy) phenyl) methythio-3\text{-}propionic acid\)

\[
\begin{array}{c}
\text{CH} - \text{O} - \text{C} - \text{S} - \text{S} - \text{COOH}
\end{array}
\]

The desired material was prepared according to the procedure of Example 19, except starting with 4-(2-naphthylmethoxy)phenyl 4-(2-quinolylmethoxy)phenyl ketone.

Example 21

Preparation of \((\text{bis}(4\text{-}(2\text{-quinoly} methoxy) phenyl)-2\text{-thienyl})\text{methythio-2-benzoic acid}\)

\[
\begin{array}{c}
\text{CH} - \text{O} - \text{C} - \text{S} - \text{S} - \text{COOH}
\end{array}
\]
The desired material was prepared according to the procedure of Example 2, except substituting 2-mercaptobenzoic acid for mercaptoacetic acid.

**Example 22**

Preparation of (4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)methylthio-2-benzoic acid

![Chemical structure of Example 22](image)

The desired material was prepared according to the procedure of Example 21, except starting with 4-(2-benzothiazolylmethoxy)phenyl 4-(2-quinolylmethoxy)phenyl ketone.

**Example 23**

Preparation of 1-(bis(4-(2-quinolylmethoxy)phenyl)-1-ethylthio-2-benzoic acid

![Chemical structure of Example 23](image)

The desired material was prepared according to the procedure of Example 1, except substituting 2-mercaptobenzoic acid for mercaptoacetic acid.

**Example 24**

Preparation of 1-((4-(2-naphthylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)-1-ethylthio-2-benzoic acid

![Chemical structure of Example 24](image)
The desired material was prepared according to the procedure of Example 23, except starting with 4-(2-naphthyImethoxy)phenyl 4-(2-quinolylimethoxy)phenyl ketone.

**Lipoxygenase Inhibition Determination in vitro**

Inhibition of leukotriene biosynthesis was evaluated in vitro using an assay involving calcium ionophore-induced LTB₄ expressed in human polymorphonuclear leukocytes (PMNL). Human PMNL isolated from heparinized (20 USP units/mL) venous blood (25 mL) obtained from healthy volunteers was layered over an equal volume of Ficoll-Hypaque Mono-Poly Resolving Medium (ICN Flow, Costa Mesa, CA) and centrifugated at 400 x g for 40 minutes at 20°C. The PMNL was collected, erythrocytes lysed and washed 2x and suspended at 1.0 x 10⁷ cells/mL in Earle's balanced salt solution with 17 mM Earle's HEPES. Aliquots of the cell suspension were preincubated with test compounds dissolved in DMSO (final concentration <2%) for 15 minutes and stimulated with calcium ionophore (final concentration 8.3 μM) for 10 minutes at 37°C. Incubations were stopped with the addition of two volumes of ice-cold methanol followed by centrifuging the cell suspensions at 4°C for 10 minutes at 450 x g. The amount of LTB₄ in the methanol extract was analyzed by enzyme-linked immunoassay or by HPLC analysis.

The compounds of this invention inhibit leukotriene biosynthesis as shown by the data for representative Example 1 with an IC₅₀ of 0.23 μM.

**Lipoxygenase Inhibition Determination in vivo**

Inhibition of leukotriene biosynthesis in vivo was evaluated using the Ionophore A32187-Induced Rat Pleural Inflammation Model. Pleural inflammation was induced in male rats following the method of Rao, et al. (Rao, T. S., Currie, J. L., Shaffer, A. F., Isakson, P. C., (1993) Evaluation of 5-lipoxygenase Inhibitors, Zileuton, A-78773 and ICI D-2138 in an Ionophore (A-23187) Induced Pleural Inflammation Model in the Rat. *Life Sciences*, **53**: 147 (1993)). Rats were dosed with experimental compounds in 0.2% methocel one hour prior to the intrapleural injection of the calcium ionophore, A23187. The rats were lightly anesthetized with Pentane (Abbott Laboratories) and injected intrapleurally with 0.5 ml of 2% ethanol in injectable saline (Abbott Laboratories) containing 20 μg of A23187 (Cal BioChem-Novabiochem). Thirty minutes later the animals were euthanised and the pleural cavities lavaged with ice cold saline (Abbott Laboratories). The lavage fluid was then added to ice cold methanol (final methanol concentration 30%) to lyse cells and
precipitate protein. Eicosanoids were determined by enzyme immunoassay by standard methods.

The compounds of this invention inhibit leukotriene biosynthesis as shown by the data for representative Example 1 with an ED$_{50}$ of 1.1 mg/kg.
WHAT IS CLAIMED IS:

1. A compound of formula:

\[
\begin{array}{c}
W^1-\text{CH}_2\text{O-} \quad \text{S}\quad \text{Y}\quad \text{COM} \\
\text{W}^2-\text{OCH}_2-\text{W}^3
\end{array}
\]

or a pharmaceutically acceptable salt thereof;

wherein \( W^1 \) and \( W^2 \) are independently selected from the group consisting of

(a) quinolyl;

(b) quinolyl substituted with a substituent selected from the group consisting of

halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms, and
alkoxy of one to six carbon atoms;

(c) benzothiazolyl;

(d) benzothiazolyl substituted with a substituent selected from the group consisting of

halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms, and
alkoxy of one to six carbon atoms;

(e) benzoxazolyl;

(f) benzoxazolyl substituted with a substituent selected from the group consisting of

halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms, and
alkoxy of one to six carbon atoms;

(g) benzimidazolyl;

SUBSTITUTE SHEET (RULE 26)
(h) benzimidazolyl substituted with a substituent selected from the group consisting of
    halogen,
    alkyl of one to six carbon atoms,
    haloalkyl of one to six carbon atoms, and
    alkoxy of one to six carbon atoms;

(i) quinoxalyl;

(j) quinoxalyl substituted with a substituent selected from the group consisting of
    halogen,
    alkyl of one to six carbon atoms,
    haloalkyl of one to six carbon atoms,
    alkoxy of one to six carbon atoms,
    pyridyl, and
    pyridyl substituted with a substituent selected from the group consisting of
    halogen,
    alkyl of one to six carbon atoms, and
    alkoxy of one to six carbon atoms;

(k) naphthyl;

(l) naphthyl substituted with a substituent selected from the group consisting of
    halogen,
    alkyl of one to six carbon atoms,
    haloalkyl of one to six carbon atoms, and
    alkoxy of one to six carbon atoms;

R¹ and R² are independently selected from the group consisting of:
(a) hydrogen.
(b) alkyl of one to six carbon atoms.
(c) haloalkyl of one to six carbon atoms,
(d) alkoxy of one to six carbon atoms, and
(e) halogen.
R₃ is selected from the group consisting of:
(a) thienyl,
(b) furyl,
(c) phenyl,
(d) naphthyl,
(e) benzo[b]thienyl,
(f) alkyl,
(g) hydroxyl, and
(h) hydrogen.

Y is an alkylene of one to six carbon atoms; and

M is selected from the group consisting of
a) a pharmaceutically acceptable metabolically cleavable group,
(b) -OR⁴ where R⁴ is selected from the group consisting of hydrogen and alkyl of one to six carbon atoms,
(c) -NR⁵R⁶ where R⁵ and R⁶ are independently selected from the group consisting of

hydrogen,
alkyl of one to six carbon atoms,
hydroxy, and
alkoxy of one to six carbon atoms,
or R⁵ and R⁶ taken together define a five- to eight-membered ring, with the proviso that R⁵ and R⁶ may not simultaneously be hydroxyl,
(d) -NR⁴SO₂R⁷ wherein R⁴ is as defined above and R⁷ is alkyl of one to six carbon atoms,
(e) -NH-Tetrazolyl, and
(f) glycyl.

2. The compound according to Claim 1, wherein W¹ and W² are independently selected at each occurrence from the group consisting of optionally substituted quinolyl, benzothiazolyl, naphthyl, and benzimidazolyl.
3. The compound according to Claim 1, wherein W¹ and W² are at each occurrence quinolyl or quinolyl substituted with a substituent selected from the group consisting of (a) quinolyl, (b-1) halogen, (b-2) alkyl of one to six carbon atoms, (b-3) haloalkyl of one to six carbon atoms, and (b-4) alkoxy of one to six carbon atoms.

4. The compound according to Claim 1 selected from the group consisting of:

1,1-bis(4-(2-quinolylmethoxy)phenyl)eth-1-ylthioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthioacetic acid sodium salt,
(bis(4-(2-quinolylmethoxy)phenyl)methylthioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-phenyl)methylthioacetic acid,
1,1-bis(4-(2-quinolylmethoxy)phenyl)-phenyl-1-penty1thioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-fury1)methylthioacetic acid;
(4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-thienyl)methylthioacetic acid,
(4-(6-fluoro-2-quinolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-
phenyl)methylthioacetic acid,
(4-(1-methyl-2-benzimidazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-
2-thienyl)methylthioacetic acid,
(4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl-2-fury1)methylthioacetic acid,
1-(4-(2-naphthylmethoxy)phenyl)-1-(4-(2-quinolylmethoxy)phenyl)-1-
ethy1thioacetic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-2-naphthyl)methylthioacetic acid,
(4-(2-naphthylmethoxy)phenyl)-(4-(2-quinolylmethoxy)phenyl)-2-
naphthyl)methylthioacetic acid,
(2-benzo[b]thienyl-bis(4-(2-quinolylmethoxy)phenyl))methylthioacetic acid,
(2-benzo[b]thienyl-4-(1-methyl-2-benzimidazolylmethoxy)phenyl-4-(2-
quinolylmethoxy)phenyl)methylthioacetic acid;
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthio-3-propionic acid.
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthio-2-propionic acid;
4-(2-benzo[b]thienylmethoxy)phenyl-bis(4-(2-quinolylmethoxy)phenyl)methylthio-3-
propionic acid.
(4-(2-benzo[b]thienyl-4-(2-naphthylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)methylthio-3-propionic acid,
(bis(4-(2-quinolylmethoxy)phenyl)-2-thienyl)methylthio-2-benzoic acid, 
(4-(2-benzothiazolylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)-methylthio-2-benzoic acid, 
1-(bis(4-(2-quinolylmethoxy)phenyl)-1-ethylthio-2-benzoic acid; and 
1-(4-(2-naphthylmethoxy)phenyl-4-(2-quinolylmethoxy)phenyl)-1-ethylthio-2-benzoic acid.

5. A method for inhibiting lipoxygenase activity or leukotriene biosynthesis in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of Claim 1.

6. A composition for inhibiting lipoxygenase activity or the biosynthesis of leukotrienes comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of Claim 2.

7. A composition for inhibiting lipoxygenase activity or the biosynthesis of leukotrienes comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of Claim 3.

8. A composition for inhibiting lipoxygenase activity or the biosynthesis of leukotrienes comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of Claim 4.
# INTERNATIONAL SEARCH REPORT

**International Application No:**

PCT/US 97/17265

## A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>IPC</th>
<th>C07D215/14</th>
<th>C07D409/14</th>
<th>C07D405/14</th>
<th>C07D417/14</th>
<th>A61K31/47</th>
</tr>
</thead>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

<table>
<thead>
<tr>
<th>IPC</th>
<th>C07D409/14</th>
</tr>
</thead>
</table>

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP 0 399 818 A (MERCK FROSST CANADA INC)</td>
<td>1-8</td>
</tr>
<tr>
<td></td>
<td>28 November 1990</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see claims 2,6</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document but published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority data claimed
  *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
  *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  *Z* document member of the same patent family

**Date of the actual completion of the international search:**

26 January 1998

**Date of mailing of the international search report:**

06.02.98

**Name and mailing address of the ISA**

European Patent Office, P.B. 5818 Patentlaan 2

NL - 2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx 31551 apo nl,

Fax: (+31-70) 340-3016

**Authorized officer**

De Jong, B

Form PCT/ISA/310 (Second sheet) (July 1992)
**INTERNATIONAL SEARCH REPORT**

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 5
   
   Although claim 5 is directed to a method of treatment of the animal/human body, the search has been carried out and based on the effects of the of the alleged composition/compound.

2. 
   
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. 
   
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this International application, as follows:

1. 
   
   As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. 
   
   As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. 
   
   As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. 
   
   No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 0399818 A</td>
<td>28-11-90</td>
<td>AT 126509 T</td>
<td>15-09-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 5581190 A</td>
<td>13-12-90</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2017376 A</td>
<td>24-11-90</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69021639 D</td>
<td>21-09-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69021639 T</td>
<td>15-02-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2065910 C</td>
<td>24-06-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3072459 A</td>
<td>27-03-91</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 7103107 B</td>
<td>08-11-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5104882 A</td>
<td>14-04-92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5204358 A</td>
<td>20-04-93</td>
</tr>
</tbody>
</table>